<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03957707</url>
  </required_header>
  <id_info>
    <org_study_id>2018-222</org_study_id>
    <nct_id>NCT03957707</nct_id>
  </id_info>
  <brief_title>Sterotactic Operation Integrating With Thrombolysis in Basal Ganglion Hemorrhage Evacuation</brief_title>
  <acronym>SOITBE</acronym>
  <official_title>Sterotactic Operation Integrating With Thrombolysis in Basal Ganglion Hemorrhage Evacuation: a Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo No. 1 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo Medical Center Lihuili Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Wenling Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Zhuji Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taizhou Hospital of Zhejiang Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinhua Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huizhou Municipal Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Quzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Sixth Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Jiaxing University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spontaneous cerebral hemorrhage is one of the main causes of death and disability all over&#xD;
      the world, accounting for 20%-30% of all cerebrovascular diseases. Minimally invasive surgery&#xD;
      of cerebral hemorrhage, especially puncture aspiration, can improve early and long-term&#xD;
      neurological recovery in patients with cerebral hemorrhage. Until now, no standardized&#xD;
      practice for minimally invasive surgery of spontaneous cerebral hemorrhage has been&#xD;
      established. Hematoma puncture and drainage based on CT scans without precise localization&#xD;
      and personalized approach design, which may lead to poor efficacy and high risk of&#xD;
      complications. Our hospital has much experience in treating cerebral hemorrhage with&#xD;
      stereotactic puncture and aspiration. So we conduct a prospective multicenter randomized&#xD;
      controlled clinical trial to determine the therapeutic effects of puncture aspiration plus&#xD;
      thrombolysis treatment for the perioperative and long-term recovery of patients with small to&#xD;
      moderate hematoma in deep basal ganglia via computerized precision coordinates and&#xD;
      personalized approach design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of ADL score</measure>
    <time_frame>6 months</time_frame>
    <description>ADL: Activities of Daily Living, ranges from 0-100, a higher ADL score means a better situation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>improvement of muscle strength of the hemiplegic limb or aphasia</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in GOS score</measure>
    <time_frame>6 months</time_frame>
    <description>GOS: Glasgow Outcome Scale, ranges from 1-5, a higher GOS score means a better situation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematoma clearance rate</measure>
    <time_frame>1 day and one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GCS score</measure>
    <time_frame>one month</time_frame>
    <description>GCS: Glasgow Coma Scale, ranges from 3-15, a higher GCS score means a better situation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Basal Ganglia Haematoma</condition>
  <arm_group>
    <arm_group_label>stereotactic surgery with drugs treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>drugs treatment alone</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>stereotactic surgery plus thrombolysis</intervention_name>
    <description>stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent</description>
    <arm_group_label>drugs treatment alone</arm_group_label>
    <arm_group_label>stereotactic surgery with drugs treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of spontaneous basal ganglia hemorrhage by imaging (CT, CTA, etc.) with a&#xD;
             volume &lt; 30 mL calculated by ABC/2 formula and Glasgow Coma Scale score ≥ 9.&#xD;
&#xD;
          2. With dysfunction such as hematoma-related motor aphasia, sensory aphasia, hemiplegic&#xD;
             limb muscle strength ≤ grade 3 or NIHSS score ≥ 15 points.&#xD;
&#xD;
          3. Hematoma stability shown by a CT scan at least 6 hours after the diagnostic CT&#xD;
             (hematoma volume increase &lt; 5 ml by ABC/2 formula)&#xD;
&#xD;
          4. Diagnostic CT scan should be obtained within 24 hours after the onset of symptoms.&#xD;
             Cases with unclear onset time should be excluded.&#xD;
&#xD;
          5. Randomization within 72 hours after diagnostic CT.&#xD;
&#xD;
          6. Surgery should be performed within 72 hours after onset.&#xD;
&#xD;
          7. SBP &lt;180 mmHg maintained for 6 hours prior to randomization.&#xD;
&#xD;
          8. Age between 18-70 years old.&#xD;
&#xD;
          9. mRS score ≤ 1 in past medical history.&#xD;
&#xD;
         10. Patients who are suitable and willing to be randomized to &quot;puncture aspiration +&#xD;
             urokinase&quot; or conservative medical treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hematoma involves other structures such as the thalamus and midbrain.&#xD;
&#xD;
          2. Mass effect or hydrocephalus due to intraventricular hemorrhage.&#xD;
&#xD;
          3. Imaging-based diagnosis of cerebrovascular abnormalities such as ruptured aneurysm,&#xD;
             arteriovenous malformation (AVM) and moyamoya disease as well as hemorrhagic&#xD;
             transformation of ischemic infarct and recent recurrence (within 1 year) of cerebral&#xD;
             hemorrhage.&#xD;
&#xD;
          4. Manifestation of early stage cerebral herniation such as ipsilateral pupil changes and&#xD;
             midline shift exceeding 1 cm.&#xD;
&#xD;
          5. Patients with unsteady hematoma or with progression to intracranial hypertension&#xD;
             syndrome.&#xD;
&#xD;
          6. Patients with any irreversible coagulopathy or known coagulation disorders; platelet&#xD;
             count &lt;100,000; INR &gt; 1.4.&#xD;
&#xD;
          7. Patients requiring long-term use of anticoagulants.&#xD;
&#xD;
          8. Patients taking dabigatran, apixaban and/or rivaroxaban (or similar drugs of the same&#xD;
             category) before symptoms arise.&#xD;
&#xD;
          9. Bleeding in other sites, including retroperitoneal, gastrointestinal, genitourinary or&#xD;
             respiratory tract bleeding; superficial or skin surface bleeding mainly occurring in&#xD;
             the vascular puncture site or transvenous approach (eg. arterial puncture, venous&#xD;
             incision, etc. ) or in the recent surgical site.&#xD;
&#xD;
         10. May be pregnant in the near future or already pregnant.&#xD;
&#xD;
         11. Previously enrolled in this study.&#xD;
&#xD;
         12. Participating in other interventional medical research or clinical trials at the same&#xD;
             time.&#xD;
&#xD;
             Patients enrolled in observational, natural history and/or epidemiological studies&#xD;
             (without intervention) are eligible for this trial.&#xD;
&#xD;
         13. Patients with an expected survival of less than 6 months.&#xD;
&#xD;
         14. Patients with severe co-morbidity (including hepatic, renal, gastrointestinal,&#xD;
             respiratory, cardiovascular, endocrine, immune and/or hematological disorders) which&#xD;
             may affect the outcome assessment.&#xD;
&#xD;
         15. Patients with mechanical heart valve. Biological valves are acceptable.&#xD;
&#xD;
         16. Patients with risk of embolism (including a history of left heart thrombus, mitral&#xD;
             stenosis with atrial fibrillation, acute pericarditis or subacute bacterial&#xD;
             endocarditis). Atrial fibrillation without mitral stenosis is acceptable.&#xD;
&#xD;
         17. Investigators believe co-morbidities would be detrimental to the patient when the&#xD;
             study begins.&#xD;
&#xD;
         18. Patients difficult to follow up or with poor compliance due to various reasons (such&#xD;
             as geographical and social factors, drug or alcohol abuse, etc.)&#xD;
&#xD;
         19. Patient or his or her legal guardian/representative is unable or unwilling to give the&#xD;
             written informed consent.&#xD;
&#xD;
         20. Patients is in a condition that is not suitable for &quot;puncture aspiration + urokinase&quot;&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>the Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>gao chen</last_name>
      <phone>8613805716226</phone>
      <email>d-gaochen@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 19, 2019</study_first_submitted>
  <study_first_submitted_qc>May 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>basal ganglion hemorrhage</keyword>
  <keyword>stereotactic surgery</keyword>
  <keyword>thrombolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganglion Cysts</mesh_term>
    <mesh_term>Synovial Cyst</mesh_term>
    <mesh_term>Basal Ganglia Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

